EXAS Valuation

Exact Sciences Corp

Add to Watchlist

Advanced Chart

50.160

+1.8(3.722%)1D

Overview
Forecast
Valuation
Earnings

EXAS Relative Valuation

EXAS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EXAS is overvalued; if below, it's undervalued.

Historical Valuation

Exact Sciences Corp (EXAS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.98 is considered Undervalued compared with the five-year average of -66.56. The fair price of Exact Sciences Corp (EXAS) is between 54.87 to 138.31 according to relative valuation methord. Compared to the current price of 50.16 USD , Exact Sciences Corp is Undervalued By 8.58%.

Relative Value

Fair Zone

54.87-138.31

Current Price：50.16

8.58%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.97

P/B

Median3y

3.60

Median5y

4.35

2.04

FCF Yield

Median3y

-1.25

Median5y

-1.20

Competitors Valuation Multiple

The average P/S ratio for EXAS's competitors is 4.29, providing a benchmark for relative valuation. Exact Sciences Corp Corp (EXAS) exhibits a P/S ratio of 2.98, which is -30.56% above the industry average. Given its robust revenue growth of 10.86%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap